56 completed. 56 Phase 3, 7 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 56 | Completed 56 |
| Phase 2 | 7 | Completed 7 |
Follow Hematologic Neoplasms: new trials by email Literature Review of Hematologic Neoplasms trials Research Report on Hematologic Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate P1101 in Japanese PV Patients P1101, Low-dose aspirin, Phlebotomy - Polycythemia Vera (PV) | Phase 3 | Completed | PharmaEssentia Japan K.K. | 21 | 2023-10-17 | 2024-11-08 |
| Haplo-PBSC+Cord vs Haplo-PBSC+BM for Hematological Malignancies Undergoing Allo-HSCT PBSCs, Cord, BMSCs - Hematological Malignancies, Hematopoietic Stem Cell Transplantation | Phase 3 | Completed | Nanfang Hospital, Southern Medical University | 314 | 2022-02-15 | 2024-08-13 |
| Rose Geranium in Sesame Oil Nasal Spray for the Improvement of Nasal Vestibulitis Symptoms in Cancer Patients Receiving Chemotherapy Placebo Administration, Questionnaire Administration, Rose Geranium in Sesame Oil Nasal Spray - Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm | Phase 3 | Completed | Mayo Clinic | 106 | 2020-11-13 | 2025-12-03 |
| Self-Management Program and Survivorship Care Plan in Improving the Health of Cancer Survivors After Stem Cell Transplant Best Practice and Internet site with links to existing resources, Internet, Mobile app and Telehealth Intervention, Survey Administration - Hematopoietic and Lymphoid Cell Neoplasm | Phase 3 | Completed | Fred Hutchinson Cancer Center | 546 | 2020-10-29 | 2025-01-29 |
| Expanded Access of Omidubicel, for Allogeneic Transplantation in Patients With Hematological Malignancies omidubicel - Hematological Malignancies | Phase 3 | Completed | Gamida Cell ltd | 36 | 2020-07-08 | 2026-06-22 |
| A Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma Carfilzomib, Lenalidomide, Dexamethasone - Relapsed or Refractory Multiple Myeloma | Phase 3 | Completed | Amgen | 454 | 2019-05-08 | 2024-08-13 |
| Expressive Helping for Stem Cell Transplant Patients Expressive Helping, Factual Writing - Stem Cell Transplantation, Hematologic Malignancy | Phase 3 | Completed | Northwestern University | 405 | 2019-03-06 | 2023-05-06 |
| Therapeutic Virtual Reality : Impact on the Management of Pain and Anxiety Related to Hematology Care (REVEH) Virtual Reality, Kalinox - Hematologic Neoplasms | Phase 2 / Phase 3 | Completed | Weprom | 126 | 2018-09-06 | 2020-06-23 |
| Apixaban in Preventing Secondary Cancer Related Venous Thrombosis in Cancer Patients Who Have Completed Anticoagulation Therapy Apixaban - Cerebral Vein Thrombosis, Deep Vein Thrombosis | Phase 3 | Completed | Academic and Community Cancer Research United | 370 | 2017-07-14 | 2025-05-18 |
| Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard UCB in Patients With Leukemia, Lymphoma, and MDS NiCord® (omidubicel), Cord Blood Unit - Hematological Malignancies, Acute Lymphoblastic Leukemia (ALL) | Phase 3 | Completed | Gamida Cell ltd | 125 | 2016-12-16 | 2026-02-25 |
| Platelet Transfusion Requirements in Hematopoietic Transplantation Pilot Study Tranexamic Acid - Hematologic Neoplasms | Phase 3 | Completed | Ottawa Hospital Research Institute | 100 | 2016-10-01 | 2020-05-18 |
| Efficacy of Prophylactic Low Level Laser Therapy (LLLT) Performed by Nurses for Decreasing Severity of Oral Mucositis During Hematopoietic Stem Cell (HSC) Transplantation Laser treatment, Placebo - Hematologic Malignancy | Phase 3 | Completed | Institut de Cancérologie de la Loire | 234 | 2016-06-27 | 2020-01-29 |
| Studyof Allogeneic Hematopoietic Stem Cell Transplantation From One Haplotype Mismatch Related Donor or From an Unrelated Donor in Elderly Patients Allogeneic (Allo) hematopoietic stem cell transplantation - Hematologic Neoplasms | Phase 3 | Completed | Institut Paoli-Calmettes | 108 | 2016-02-23 | 2026-10-16 |
| Study of FOND Versus FOND+O for the Prevention of CINV in Hematology Patients Receiving Highly Emetogenic Chemotherapy Regimens Olanzapine, Placebo - Complications of Bone Marrow Transplant, Hematologic Neoplasms | Phase 3 | Completed | Augusta University | 108 | 2015-11-01 | 2018-08-20 |
| Peg Interferon α-2b for Relapsed Hematological Malignancies After Allo-HSCT Peg interferon alfa-2b - Hematological Neoplasms, Recurrence | Phase 2 / Phase 3 | Completed | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 30 | 2015-08-01 | 2023-03-16 |
| Study to Assess the Self-administration of AOP2014 Using a Pen, Developed for the Treatment of Polycythemia Vera Patients Pegylated-Proline-Interferon alpha-2b in a Pre-filled Pen - Polycythemia Vera | Phase 3 | Completed | AOP Orphan Pharmaceuticals AG | 30 | 2015-07-01 | 2016-02-17 |
| TRial to EvaluAte Tranexamic Acid Therapy in Thrombocytopenia Tranexamic acid (TXA)., Placebo - Hematologic Neoplasms, Hemorrhage | Phase 3 | Completed | NHS Blood and Transplant | 616 | 2015-06-01 | 2025-10-28 |
| Expanded Treatment Protocol (ETP) of Ruxolitinib in Patients With Polycythemia Vera Who Were Hydroxyurea Resistant or Intolerant and for Whom no Treatment Alternatives Was Available. Ruxolitinib - Polycythemia Vera | Phase 3 | Completed | Novartis Pharmaceuticals | 161 | 2014-11-21 | 2019-07-18 |
| AOP2014 vs. BAT in Patients With Polycythemia Vera Who Previously Participated in the PROUD-PV Study. Pegylated-Proline-interferon alpha-2b, Best available therapy (BAT) - Polycythemia Vera | Phase 3 | Completed | AOP Orphan Pharmaceuticals AG | 170 | 2014-11-01 | 2021-06-01 |
| Antiemetic Therapy With or Without Olanzapine in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients With Cancer Receiving Highly Emetogenic Chemotherapy Olanzapine, Chemotherapy (cisplatin or cyclophosphamide and doxorubicin), Antiemetic treatment (ondansetron or granisetron or palonosetron; plus dexamethasone; plus fosaprepitant or aprepitant) - Hematopoietic/Lymphoid Cancer, Nausea and Vomiting | Phase 3 | Completed | Alliance for Clinical Trials in Oncology | 401 | 2014-08-20 | 2025-01-28 |
Showing 20 of 56. Sign in to see all of them.
Polycythemia Vera (20) · Myeloproliferative Disorders (14) · Leukemia, Myeloid, Acute (13) · Lymphoma, Large B-Cell, Diffuse (13) · Multiple Myeloma (13) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (13) · Hodgkin Disease (12) · Leukemia, Lymphocytic, Chronic, B-Cell (12) · Lymphoma, Mantle-Cell (12) · Thrombocythemia, Essential (12) · Waldenstrom Macroglobulinemia (12) · Leukemia, Myeloid, Chronic-Phase (11) · Lymphoma, Non-Hodgkin (11) · Myelodysplastic Syndromes (11)
Hemic and Lymphatic Diseases (56) · Neoplasms by Site (56) · Hematologic Diseases (51) · Neoplasms (50) · Bone Marrow Diseases (23) · Pathological Conditions, Signs and Symptoms (21) · Bone Marrow Neoplasms (20) · Pathologic Processes (20) · Neoplasms by Histologic Type (19) · Immune System Diseases (18) · Disease Attributes (17) · Immunoproliferative Disorders (17) · Hemorrhagic Disorders (16) · Cardiovascular Diseases (15)
Hydroxyurea (5) · ruxolitinib (4) · Voriconazole (3) · Whole-Body Irradiation (3) · fludarabine phosphate (3) · peginterferon alfa-2b (3) · Aspirin (2) · Caspofungin (2) · Cyclophosphamide (2) · Cyclosporine (2) · Cyclosporins (2) · Early Intervention, Educational (2) · Lenalidomide (2) · Mycophenolic Acid (2) · Olanzapine (2)
Fred Hutchinson Cancer Center (4) · Novartis Pharmaceuticals (4) · AOP Orphan Pharmaceuticals AG (3) · Alliance for Clinical Trials in Oncology (3) · M.D. Anderson Cancer Center (3) · Memorial Sloan Kettering Cancer Center (3) · Amgen (2) · Gamida Cell ltd (2) · Incyte Corporation (2) · Ottawa Hospital Research Institute (2) · Academic and Community Cancer Research United (1) · Augusta University (1) · Azienda Ospedaliera San Giovanni Battista (1) · Case Comprehensive Cancer Center (1) · Children's Oncology Group (1)
United States (35) · France (16) · Germany (13) · Italy (13) · Spain (12) · Canada (11) · Hungary (10) · Austria (8) · Belgium (8) · Czechia (8) · Slovakia (8) · Russia (7) · Turkey (Türkiye) (7) · United Kingdom (7) · Bulgaria (6)
Heinz Gisslinger, MD (3) · Brenda Sandmaier (2) · Mitchell Horwitz, MD (2) · Agha Mounzer, MD (1) · Alan Tinmouth, MD MSc (1) · Alberto Bosi, MD (1) · Amber B Clemmons, PharmD (1) · Bernard DePrijck, MD (1) · Celia Grosskreutz, MD (1) · Charles L Loprinzi (1) · Christelle Ferra, MD (1) · Christopher C Dvorak (1) · Chun Wang, M.D., Ph.D. (1)
PMID 29396713, PMID 32499241, PMID 41890273, PMID 15459300, PMID 17397698, PMID 20525993, PMID 21467546, PMID 21856226, PMID 22207416, PMID 22480131, PMID 22814329, PMID 23109697, PMID 23502220, PMID 24335106, PMID 24532039, PMID 25478136, PMID 25629741, PMID 25961767, PMID 26700120, PMID 26700123, PMID 27020837, PMID 27102499, PMID 27410922, PMID 27798034, PMID 27916398, PMID 28193568, PMID 29253068, PMID 29477778, PMID 29906570, PMID 30287855, PMID 31248843, PMID 31399378, PMID 31515250, PMID 31606897, PMID 31615553, PMID 31982039, PMID 32083994, PMID 32665955, PMID 32781287, PMID 33136159, PMID 33811823, PMID 34157093, PMID 34670600, PMID 34932836, PMID 35007321, PMID 35597252, PMID 35662590, PMID 36642232, PMID 36790852, PMID 36999619
2014 (3), P30CA015704 (2), 2008 (1), P01CA018029 (1), P01CA078902 (1), P01CA108671 (1), P30CA015083 (1), P30CA068485 (1), R01CA126971 (1), R01CA127655 (1), R01CA160684 (1), R01CA215134 (1), R01CA223963 (1), U10CA031946 (1), U10CA095861 (1)